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Purpose: To compare the effect of a rat anti-VEGF antibody, administered either by topical or subconjunctival (SC)
routes, on a rat model of corneal transplant rejection.
Methods: Twenty-four rats underwent corneal transplantation and were randomized into four treatment groups (n=6 in
each group). G1 and G2 received six SC injections (0.02 ml 10 µg/ml) of denatured (G1) or active (G2) anti-VEGF from
Day 0 to Day 21 every third day. G3 and G4 were instilled three times a day with denatured (G3) or active (G4) anti-
VEGF drops (10 µg/ml) from Day 0 to Day 21. Corneal mean clinical scores (MCSs) of edema (E), transparency (T), and
neovessels (nv) were recorded at Days 3, 9, 15, and 21. Quantification of neovessels was performed after lectin staining
of vessels on flat mounted corneas.
Results: Twenty-one days after surgery, MCSs differed significantly between G1 and G2, but not between G3 and G4,
and the rejection rate was significantly reduced in rats receiving active antibodies regardless of the route of administration
(G2=50%, G4=66.65% versus G1 and G3=100%; p<0.05). The mean surfaces of neovessels were significantly reduced
in groups treated with active anti-VEGF (G2, G4). However, anti-VEGF therapy did not completely suppress corneal
neovessels.
Conclusions: Specific rat anti-VEGF antibodies significantly reduced neovascularization and subsequent corneal graft
rejection. The SC administration of the anti-VEGF antibody was more effective than topical instillation.
Vascular endothelial growth factor (VEGF) promotes
angiogenesis in blinding eye diseases, such as retinopathy of
prematurity, age-related macular degeneration (AMD), and
diabetic retinopathy [1]. Anti-VEGF strategies have changed
the prognosis of neovascular AMD [2,3].
While anti-VEGF antibodies have not received FDA
approval to treat neovessels growing in the anterior segment
of the eye, it has been suggested they can help treat pterygium
[4], herpetic keratitis [5],and Stevens-Johnson syndrome [6]
via topical or subconjunctival (SC) administration. In such
indications, anti-VEGFs are used at less than 100 times the
systemic doses used to treat colorectal cancer, thereby limiting
the risk of systemic side effects [7,8].
Anti-VEGF treatment administrated by the topical [9] or
SC route [10] has also been shown to reduce corneal
neovascularization in wound healing models in which
neovessels are generated by corneal injury [11] or by limbal
stem cell deficiency [12].
In corneal transplantation, preexisting vascularization of
the corneal bed is an important risk factor for immune
rejection [13-15]. The reduction of preexisting neovessels
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using anti-VEGF has been shown to improve the success of
high-risk allogeneic corneal transplantation in animal models
[16-18]. Therefore, several attempts have been made to
prevent or reduce corneal rejection using local anti-VEGF
therapies in animal models and in humans [19]. However, no
definite conclusions can be drawn from animal studies
because bevacizumab, a humanized anti-VEGF antibody that
binds poorly to murine VEGF-A, has typically been used.
Indeed, to neutralize murine VEGF-A, a 1,000 times higher
concentration of bevacizumab is required; it also dissociates
faster [20,21]. Moreover, it remains unclear whether SC
injections or topical administration is preferable in this
indication [12,22]. To address these questions, we have
evaluated the effects of a rat anti-VEGF antibody,
administered either by SC injection or topical instillation, on
corneal rejection in a rat model.
METHODS
All animal studies complied with the European Community
Standard of Care and Use of Laboratory Animals and the
Association for Research in Vision and Ophthalmology
(ARVO) Statement for the Use of Animals in Ophthalmic and
Visual Research. Protocols were approved by the ethical
committee of Paris Descartes University.
Animal model: Ten week-old Brown Norway (BN)
females rats and Lewis male rats (n=24) were obtained from
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Elevage Janvier (Le Genest Saint Isle, France). The Lewis rats
were anesthetized with a mixture of 125 mg/kg ketamine
chlorhydrate (UVA, Ivry-sur-Seine, France) and 5 mg/kg
chlorpromazine (Specia Rhône Poulenc, Paris, France). Each
animal was systematically weighed before examination and/
or experimentation procedures. For corneal transplantation,
penetrating keratoplasty (PK) was performed by two corneal
surgeons (J.L.B. and N.R.), as previously described [23]. In
brief, corneal buttons from the sacrificed BN rats were
obtained using a 3.0 mm trepan and were grafted into a 3.0 mm
corneal bed in the right eyes of the Lewis rats. The day of
surgery was Day 0. Paracentesis was performed before
trephination under maximum pupil dilation (tropicamide,
Théa, Clermont-Ferrand, France) and the anterior chamber
was filled with viscoelastic fluid (Healonid, Pharmacia,
Uppsala, Sweden). A 3.0 mm trephination was performed
using a biopsy punch and was completed with Vanas scissors.
The BN corneal button was secured in place by a 10–0
monofilament 8-path running suture (Ethicon, Saint Stevens-
Woluwe, Belgium) with a buried suture knot to limit
artifactual vascular growth. No treatment was applied at the
end of surgery other than the tested one. In this model, the
rejection process was initiated on Day 5 and was completed
by Day 14 after PK [24]. Transplanted eyes with
intraoperative or immediate post-surgical complications
before Day 2 (suture rupture, endophthalmitis, cataract, iris
herniation) were excluded and replaced by the next grafted
animal on the randomization schedule.
Neutralizing VEGF agent: We used a 150 kDa rat anti-
VEGF antibody (R & D Systems, Minneapolis, MN)
neutralizing to rrVEGF164, rmVEGF120, rmVEGF164,
rhVEGF121, or rhVEGF165, with a less than 2% cross-
reaction with VEGF B, C, and D. The antibody was aseptically
diluted with PBS (Dulbecco Sigma-Aldrich, Lyon, France) at
a dose of 10 µg/ml. The necessary volume of anti-VEGF
treatment was prepared for SC injection and topical
instillation in aliquots every day.
As a control, non-immune VEGF antibody was prepared
in the same way and was further denatured by heating at 80 °C
for 15 min.
Subconjunctival injections: Prior to the SC injections, the
rats were anesthetized with 1.5 mg/kg of chlorhydrate
ketamine and 0.23 mg/kg of chlorpromazine. The SC
injections were performed on the day of the surgical procedure
and on Days 3, 6, 9, 12, 15, and 18 before sacrifice. To prevent
trauma and take advantage of the slow release of the
therapeutic agent, injections were not performed on a daily
basis [12].
SC injections (2 µl) were performed in grafted eyes using
a 29 1/2 gauge needle (micro-fine 0.3 ml SafetyGlide™
insulin syringe; Becton, Dickinson and Company, Franklin
Lakes, NJ). Injections were performed under an optical
microscope and were situated at least 2 mm away from the
needle puncture. To reduce leakage, conjunctival punctures
were pinched with a microsurgical forceps 3 s immediately
after injection.
Treatment protocol: After PK, the rats (n=24) were
randomly assigned to four treatment groups, as follows.
Group 1 (n=6) received an SC injection of 0.02 ml denatured
10 µg/ml anti-VEGF, repeated every third day, from Day 0 to
Day 18. Group 2 (n=6) received an SC injection of 0.02 ml
10 µg/ml anti-VEGF, repeated every third day, from Day 0 to
Day 18. Group 3 (n=6) was instilled with denatured 10 µg/ml
anti-VEGF drops, three times a day, from Day 0 to Day 20.
Group 4 (n=6) was instilled with 10 µg/ml anti-VEGF drops,
three times a day, from Day 0 to Day 20. Grafted rats were
sacrificed on Day 21 using an overdose of intraperitoneal
pentobarbital (Ceva Santé Animal, Libourne, France).
Evaluation of the rejection process: Grafted corneas were
observed with a slit-lamp on Days 0, 3, 6, 9, 12, 15, 18, and
21 before treatment. Pictures of the graft were obtained at each
time point. The progression of edema and transparency and
the growth of neovessels both in the button area and in the
recipient were scored by two masked examiners, as follows
[25]. For corneal transparency: 0 (clear cornea), 1 (slight
opacity), 2 (mild opacity with iris details visible), 3 (moderate,
iris details not visible), and 4 (white cornea). For edema: 0 (no
edema), 1 (slight edema), 2 (diffuse and moderate stromal
edema), and 3 (diffuse marked stromal edema). For
neovascularization: 0 (no observable growth of new vessels),
1 (new vessels invading less than 1/3 of the recipient bed), 2
(new vessels invading less than 2/3 of the recipient bed), 3
(new vessels growing up to the limiting ring of the graft), and
4 (new vessels invading the graft). A graft was rejected when
opacity was greater than or equal to 3 [25], which is greater
than the opacity seen in isografts [26].
Corneal staining: On Day 21, the grafted rats were
sacrificed, the eyes were enucleated, and the corneas were flat
mounted in 4% paraformaldehyde for 1 h. Fixed flat mounted
corneas were rinsed with PBS, then incubated for 20 min in
20 mM EDTA (Sigma-Aldrich Co., St. Louis, MO) to enhance
the stromal penetration of lectin protein. Corneas were post-
fixated for 1 min with iced acetone and rinsed two times with
1% triton X100/PBS. Corneas were exposed to 2% bovine
albumin serum (BSA) for 1 h at room temperature and were
then incubated with 1:100 TRITC conjugated G.
Simplicifolia (Bandeiraea) isolectin (Sigma-Aldrich) in 1%
triton X100/PBS overnight at 4 °C. Each slide was rinsed three
times in PBS and mounted in PBS:glycerol (1:1).
After we ensured there was no autofluorescence, images
of flat mounted corneas were captured using Olympus
fluorescence microscopy (Olympus America Inc.,Center
Valley, PA) at 550 nm and 20× magnification and were
digitally stored for analysis. Image J software (Wayne
Rasband, NIMH, Bethesda, MD) was used to conduct
fluorescent morphometric analysis, which quantified the
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percentage of neovascularized corneas within the limbus
boundaries as opposed to the total corneal area.
Statistical analysis: Bodyweight modifications were
assessed by comparing the mean bodyweights between time
points using a Mann–Whitney test. Rejection scores, mean
clinical scores (MCSs), and neovascularization areas were
also compared using a Mann–Whitney non-parametric test, as
each single treatment group was only compared to its related
control throughout the analysis. For all comparisons, an alpha
level of <0.05 was considered significant.
RESULTS
Animals: Six animals were excluded within 2 days after the
procedure (1 from Group 1, 2 from Group 2, 2 from Group 3,
and 1 from Group 4) due to four cases of endophthalmitis (1
from Group 1, 2 from Group 2, and 1 from Group 3) and two
discontinuations of the running suture (1 from Group 3 and 1
from Group 4). Each animal was replaced following the
randomization schedule. Before experimentation, the average
weight of grafted rats from Groups 1, 2, 3, and 4 was 321.5 g,
312.9 g, 315.6 g, and 322.9 g; these did not change much
throughout the study (p>0.1).
Clinical evaluation of the rejection process: On Day 21 before
the BN rats were sacrificed, all those in the control groups (G1
and G3) experienced corneal rejection, while three grafts
(50%) and four grafts (66.67%) were rejected in G2 and G4,
respectively. The treated groups experienced significantly
less rejection than their respective control groups (G1 versus
G2, p<0.005; G3 versus G4, p<0.05; Figure 1).
The MCSs for transparency, edema, and
neovascularization are illustrated at Day 9, Day 15, and Day
21 after transplantation in Figure 2A,B. Even when there was
no statistical significance; the MCSs were always lower for
all assessed parameters in the treated groups compared to their
related control groups. At each time point, the MCSs for
neovascularization were significantly lower in the treated
groups compared to the control groups, except at the end of
the experiment for the topically treated group (G3 versus G4
at D21, p>0.05). Compared to the control group, edema in the
SC treated group differed significantly only after Day 15.
Conversely, whether topically treated buttons displayed
significantly more edema during the acute phase of rejection
at Day 9, no statistical difference was found at later time
points. Transparency MCSs reached a statistical difference at
every time point for SC injected eyes, while eyes treated with
drops only differed at Day 15.
Neovascularized area of corneal buttons: Total areas and
neovascularized areas of corneas are displayed in Table 1. The
total mean areas of corneas (recipient cornea and button) did
not significantly differ across groups (p>0.05).After SC
injection with anti-VEGF (G1), the mean neovascularized
area was 35.66% of the total mean cornea area compared to a
mean neovascularized area of 57.82% after SC injection with
denatured anti-VEGF (G2; p<0.005; Figure 3). After topical
treatment (G3), the mean neovascularized area was 43.08%
of the mean corneal area compared to 57.38% for the related
controls (G4; p<0.005; Figure 3 and Table 1). Interestingly,
the neovascularized area was significantly lower in the SC
treated group than in the anti-VEGF drops group (p=0.01).
DISCUSSION
Pre-existing or secondary neovascularization predisposes to
graft rejection after corneal allogeneic transplantation [27,
28]. Neovessels arise from the limbus toward alloantigeneic
tissue, i.e., the button, under the influence of pro-
inflammatory cytokines produced by sensitized immune
active cells [15,29]. Vascular endothelial growth factors and
their receptors have been demonstrated to play a critical role
in corneal neovascularization in both humans and in animal
models [29-34]. Conversely, anti-VEGF therapy effectively
inhibits corneal neovascularization in several rabbit models
[12] as well as in patients [35].
In our study, we have chosen to administer a rat anti-
VEGF specific antibody to optimally match with the animal
model. Bock et al. demonstrated that humanized anti-VEGF
antibodies (i.e., bevacizumab) bind rat VEGF-A with less
specificity than humanized VEGF-A, and dissociate more
rapidly because of a lack of specificity [20]. It was therefore
Figure 1. Demonstrative cases on slit-lamp examination 21 days after transplantation. Control corneas receiving either topical (A) or SC (C)
denatured treatment were fully rejected with a maximum clinical score where clear grafts could be observed after topical (B) or SC (D)
administration of active anti-VEGF therapy.
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possible to administer lower doses and concentrations of anti-
VEGF antibody (0.6 µg/kg and 10 µg/ml) than in other studies
(usually 5 mg/kg and 4 mg/ml) [20,36]. Increasing species
specificity in experiments might prevent dose-dependent side
effects or unspecific events while preserving the same
efficacy. It is also likely that humanized anti-VEGF (Fab),
while being less specific, is capable of interacting with
cytokines other than VEGF itself. If so, they would potentially
act through non-VEGF-mediated pathways. It is therefore
more accurate to conclude that anti-VEGF treatment is
effective through the VEGF-mediated pathway when the
considered antibodies match animal species. Vascular
endothelial growth factor levels in the time course of corneal
graft rejection are of interest, as are other cytokine kinetics,
while neutralizing VEGF. However, this paper was designed
to compare two different routes of administering a VEGF
neutralizing antibody specific to the rat VEGF in a rat model
of corneal graft rejection in hopes of helping clinicians.
For proliferative diabetic retinopathy, VEGF levels were
measured in the range of 500 pg/ml to 1 ng/ml and the minimal
levels of neutralizing ranibizumab were evaluated at 10 µg/
ml (the levels found at four weeks after injection), not
necessarily correlating well with VEGF levels [37-39].
Hence, the observed clinical effect of anti-VEGF antibodies,
although already semi-quantified by immunofluorescence in
other studies [40,41], does not correlate well with VEGF
levels in the ocular media or tissues. This is probably because
the balance between VEGF and soluble VEGF receptors or
other cytokines would influence the clinical results.
Therefore, we think the clinical effect of two routes of
administration is of interest for clinicians who use
bevacizumab in cases of graft rejection without the benefit of
reliable preclinical studies to guide their practice [19,42-45].
Both drop instillations and SC injections are relevant to
target neovessels growing from limbal vessels [33,46]. While
ocular instillation is less invasive and systemic rates are lower
than those required for SC injections, drops also have lower
bioavailability [47,48]. The mechanism that might explain
how 150 kDa antibodies can effectively treat corneal
neovascularization remains unclear. Antibody ocular
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Figure 2. Mean clinical corneal scores observed after treatments versus matched controls. Mean  clinical scores  (±SEM) were higher in
control animals treated with denatured SC injections (A , square line) compared to those treated with SC injections of active rat anti-VEGF (A,
triangle line) for the three parameters assessed at every time point. With drop administration (B ), the scores were also higher for controls (B,
lozenge line), but not significantly after 21 days. The asterisk represents a p<0.05 statistical significance.
TABLE 1. MORPHOMETRIC QUANTIFICATION OF THE NEOVASCULARIZED CORNEAL AREA OF FLAT MOUNTED CORNEAS FROM TREATED GROUPS (G2=SC
ANTI-VEGF AND G4=TOPICAL ANTI-VEGF) AND THEIR RELATIVE CONTROLS (G1=SC INACTIVATED ANTI-VEGF AND G3=TOPICAL INACTIVATED
ANTI-VEGF).
Groups of
animals (G)
Total corneal (area
mm2±SEM)
    p
values
Neovascularized corneal
(area mm2±SEM) Ratio (%)
    p
values
    p
values
G1 113.05±3 >0.05 65.37±3.15 57.82 0.0039 0.01
G2 116.5±1.72 >0.05 41.56±3.62 35.67 0.0039 0.01
G3 114.23±1.89 >0.05 65.55±3.53 57.38 0.0039 0.01
G4 113.82±2.91 >0.05 49.03±3.94 43.07 0.0039 0.01
          A p value of <0.05 represents a significant difference.
penetration may be partially explained by the loss of corneal
barrier integrity resulting from corneal surgery. The fact that
topical instillation is less efficient in preventing neovessel
growth after PK favors this hypothesis. Another explanation
might be the limbal penetration of antibodies, as occurs with
other peptides or F(abs) [49]. Direct transepithelial
penetration of a 150 kDa protein through an intact cornea is
unlikely to occur.
In our study, SC injections and drops had the same effect
on the final rejection rate; however, SC injections decreased
edema and the progression of new vessels more efficiently at
later time points than at earlier ones, as confirmed by both
MCS quantification and neovascular surface morphometry.
Several conditions are necessary for an instilled drug to cross
the epithelial barrier, such as polarity, hydrophilia or lipohilia,
pH, osmolarity, and molecular weight [50]. The molecular
weight of bevacizumab is 149 kDa, which is almost identical
Figure 3. Flat mounted corneas stained for new vessels 21 days after allotransplantation. Allografted cornea treated with inactivated (A, B)
or active (C)  rat anti-VEGF  antibody and flat  mounted  at Day 21;  new vessels stained  with lectin  arise from  the limbus  toward  the
grafted area (A, B, C; white arrows). The progression of new vessels crossed the trephination line (A; arrow heads) across the stroma of the
button (A, black arrow) between the strand of the running suture (B, black arrow), securing the corneal graft to the recipient bed. It was limited
to the recipient area in treated animals (C; white arrows). Li, limbus; IF, interface between donor and recipient (A, C; arrowheads,). Scale
Bar=2200 µm. Magnification, A, C 20×, B 100×.
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to the rat anti-VEGF neutralizing agent used in the present
study. Even though the molecules are large, they are able to
cross the healthy corneal epithelial barrier [51]. On the other
hand, SC injections generate higher intraocular
concentrations compared to systemic or topical administration
[51] and contribute to the slower release of pharmacologic
agents. After SC injection, anti-VEGF agents have proven to
spread into the corneal stroma and to remain there for several
days [12]. This may explain why neovascularization was more
efficiently slowed down after SC injections rather than after
drop instillations in our experiments.
Doctor et al. [35] recently observed that the previously
neovascularized corneal area of eight eyes from seven patients
treated with SC injections of bevacizumab was reduced due
to ocular surface inflammatory diseases.
We tested anti-VEGF therapy on an animal model that
mimicked corneal transplantations in humans without specific
risk of rejection, such as preexisting neovascularization, to
compare the two main local routes of administration
commonly used to treat corneal diseases. To the best of our
knowledge, a comparison of the efficacy between topical and
SC administration has not been previously reported.
Bachmann et al. used a high-risk graft rejection model to
efficiently inhibit postoperative hemangiogenesis,
lymphangiogenesis, the recruitment of antigen-presenting
cells, and to improve corneal graft survival [16,52].
Animal models of corneal transplantation frequently use
incorrect pathways to eventually mimic rejection. For
example, models using separate sutures [53,54] might induce
interfering inflammatory reactions [16] that are difficult to
distinguish from true immune reactions. In the present model,
we assumed that a continuous suture would limit irrelevant
stimulations and minimize the unavoidable
neovascularization that would occur when any persistent
corneal foreign body, such as sutures, is present. Cursiefen et
al. [53] observed that a total inhibition of corneal sutures
induced neovascularization with a VEGF-A trap targeting
VEGF and placental growth factor (PlGF). Using the same
pathway, we only observed partial inhibition. This could
argue against a similar effect of VEGF-A on neovessel
induction during the inflammatory (foreign body) or
alloimmune process.
Our results show that SC anti-VEGF injections decreased
corneal neovascularization and increased the graft survival
rate, reducing the neovascularized area by more than 20%
(p<0.005). Topical treatment reduced it by approximately
15% compared to the control group (p<0.005) from Day 9
after the graft surgery until sacrifice. Thus, both routes seem
to reduce the progression of corneal vascularization.
However, combining the slow release effect and targeting
anti-VEGF therapy to the precise location of early
neovascularization during the rejection process (the limbus),
SC administration seems more efficient than simple drops.
The slight difference observed between the SC injection and
topically treated groups in reducing neovascularization might
also reflect higher volumes of anti-VEGF administered under
the conjunctiva, which could act as a reservoir, gradually
releasing drugs and permitting higher absorption by tissues.
We also assume that immediate post-operative SC injection
also limited the high amount of proinflammatory cytokines
(TNF- α, IL-1) and growth factors (TGF-α, TGF-β, b-FGF,
PDGF, and VEGF) produced by corneal fibroblasts migrating
toward the wound at the early stage of wound healing (about
4 days in rats), thus possibly contributing to a non-immune
proangiogenic environment.
Although significant, we only observed a slowdown in
neovascular progression rather than a complete inhibition for
the treated animals. This partial effect might be due to our
treatment, which mainly targeted VEGF A, with less than 2%
inhibiting cross-reactions with VEGF-B, C, and D. No
antibody is currently available for rats to inhibit the VEGFR-3
lymphangiogenesis pathway. In a mouse model, Lyve-1
antibodies against VEGFR-3 inhibited new lymphatic vessels
and dramatically limited graft rejection [17]. Furthermore,
many other growth factors contribute to the graft rejection
process, such as PlGF [55], TGF-α, TGF-β, bFGF, PDGF, or
other VEGF independent factors such as IL-1β, IL- 6, or TNF
[56]. To totally inhibit new vessels by acting on a single
pathway therefore seems difficult. It is likely, however, that
the global neovascularization process would not be affected
only by VEGF inhibition. Hopefully, a therapeutic
combination targeting the relevant cytokine group, possibly
associated with additional methods such as gene therapy,
would be more efficient.
The MCSs did not differ between treated and control
animals, although they were slightly but constantly lower in
the treated groups. This result suggests a possible inhibition
that would not have been noticeable due to a lack of statistical
power. A 90% statistical power combined with a 25% initial
maximum risk (risk to obtain no spontaneous rejection in our
model) would reveal a 135% relative risk reduction for
rejection. In other words, the treatment should have been
extremely efficient and the results should have been
particularly clear cut, reaching statistical significance among
groups of six animals. On the other hand, treated animals
should be operated on the same day as their relative controls
to prevent any procedural bias from interfering with clinical
observations and outcomes. However, performing surgery on
more than 12 usable animals in a single day would have
rendered the experiment design unrealistic.
We repeated SC injections every 3 days, with low anti-
VEGF concentrations (10 µg/ml compared to a range from 4
to 25 mg/ml for the usual concentration). We did not
administer injections on a daily basis to limit local trauma and
prevent local inflammation from interfering with the natural
rejection process. Further work should certainly assess the
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optimal frequency for injections to obtain clinical efficiency.
The optimal frequency for administering drops should also be
explored as it is possible that more instillations would reduce
the rejection rate or reduce the neovascularized area.
We attribute the relative graft survival observed after
VEGF inhibition to a combination of mechanisms. The
alloimune response occurring in corneal transplantation
mainly involves T lymphocytes and antigen-presenting cells.
The latter is thought to be driven to allogeneic corneal tissue
through hematic and lymphatic vessels, growing from the host
limbus under VEGF cytokine stimulation. By blocking
VEGFR 2 and 3 pathways, anti-VEGF drugs inhibit the
afferent route of immune response, which is critical for the
sensitization of antigen-presenting cells. Additionally, VEGF
inhibition directly affects the recruitment of inflammatory
cells in the cornea [17], where neutrophilic polynuclear and
macrophages are retained [57]. However, VEGF is not
entirely inhibited because immunocompetent cells also
produce hemangiogenic and lymphangiogenic growth factors
[16,53].
Our observations are limited to rats. Species differences
must be taken in account to apply the present results to human
corneal transplantation. In a murine model, graft rejection is
faster (delays of 4–10 days have been noted in previously
immunized people), and both wound healing and immune
reactions are exacerbated. Endothelial division is possible and
the distance between graft and limbus differs. However, we
can suggest some conclusions. From a histological and
embryological point of view, tissues and observations are
rather similar for both human and rat cornea organoculture
[58,59].
According to our results, a specific to species anti-VEGF
antibody is efficient for partial inhibition of corneal
neovascularization. It increases the corneal graft survival rate
in a rat model, but statistically significant results were only
reached for the SC route of administration. Our experimental
observations corroborate previous observations concerning
the control of corneal neovascularization in humans. More
experiments are needed to answer the key questions, which
are how much VEGF is expressed in the cornea during the
rejection time course and how much should be neutralized.
How much the anti-VEGF antibodies administered by the two
methods of administration are eventually existing in the target
tissues is another interesting point. In the treatment of
exsudative AMD and proliferative diabetic retinopathy,
bevacizumab (Avastin®) is successfully used intra-oculary to
control retinal and choroidal neovascularization; it has a low
rate of side effects. If our results are confirmed in humans, the
use of this simple cost-effective treatment could be of major
importance for patients with a high risk of graft rejection. In
conclusion, the present results are encouraging and support
the further use of anti-VEGF in human clinical practice to treat
corneal graft rejection using the SC route of administration.
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